A publication titled "Pharmacological management of obesity: Current landscape and emerging therapies" was published on September 1, 2026, in the Indian Journal of Pharmacology. The article references survodutide, an investigational compound that remains classified as unapproved and under research. This publication is listed under PubMed ID 42683980. The event data indicates this is a new publication rather than a study reporting original trial results. No findings, outcomes, or efficacy data from the publication are included in this brief. Survodutide's regulatory status remains unapproved for research use only, and no claims of safety or benefit can be drawn from the existence of this publication alone. Readers interested in the broader context of obesity pharmacotherapy and where survodutide fits among emerging therapies may wish to consult the full article via the source link provided. For more background on survodutide, including its development status and mechanism, readers can refer to the compound overview page.
Survodutide Featured in New Obesity Pharmacotherapy Review
See the full survodutide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42683980/